Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6946697 | 0.84 | REN (0.39) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6941270 | 0.79 | GBA1 (0.42) | — | |
| SCHEMBL5870737 | 0.71 | PRMT5 (0.43) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL8751343 | 0.67 | IDO1 (0.50) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL13389492 | 0.67 | PRMT5 (0.46) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL15807220 | 0.66 | SLC6A4 (0.54) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL6839637 | 0.66 | SLC6A3 (0.36) | SLC6A4SLC6A3KCNH2 | |
| SCHEMBL6839640 | 0.66 | SLC6A3 (0.36) | SLC6A4SLC6A3KCNH2 | |
| SCHEMBL13407641 | 0.66 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL13389509 | 0.66 | PRMT5 (0.45) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194790-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | GONG LEYI | 2006-08-31 | — | — | US | disclosed |
| US-20060189596-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | GONG LEYI | 2006-08-24 | — | — | US | disclosed |
| US-7081531-B2 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2006-07-25 | — | — | US | disclosed |
| EP-1599472-A1 | CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004076448-A1 | CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-10 | — | — | WO | disclosed |
| US-20040176416-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | ROCHE PALO ALTO LLC | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189596-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | CCR3, CCR10, CCR1 | SLC6A2 2346/4885SLC6A4 2246/4885SLC6A3 1381/4885 |
| US-20040176416-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | CCR3, CCR1, CCR10 | SLC6A2 1955/4885SLC6A4 1637/4885SLC6A3 1442/4885 |
| US-20060194790-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | CCR3, CCR10, CCR1 | SLC6A2 1937/4885SLC6A4 1319/4885SLC6A3 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.